The ECOG E4A03 study found that Revlimid plus low-dose dexamethasone improved three-year overall survival rates to 75% in the intent-to-treat population. Continuous therapy also achieved a 91% overall response rate with a high complete response and very good partial response rate.
Phase II trials demonstrate significant activity of pomalidomide in MM and myelofibrosis, with disease improvement or stabilization in 76% of patients. Pomalidomide also shows promise in patients who previously did not respond to REVLIMID therapy.
A landmark analysis found that continuous treatment with Revlimid and dexamethasone improved overall survival and time to disease progression in multiple myeloma patients. Patients who continued therapy had significantly longer overall survival rates compared to those who discontinued treatment after 10 months or less.
A phase III study will evaluate Revlimid as a maintenance therapy for elderly patients with diffuse large B-cell lymphoma. The study aims to determine progression-free survival and overall survival associated with Revlimid compared to placebo.
A Phase I study combining Revlimid and Vidaza found the combination was well-tolerated and had high activity in treating higher-risk myelodysplastic syndromes (MDS). The therapy resulted in a 39% complete response rate and 72% overall response rate among patients.